Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple ...

Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

ORLANDO -- Combining teclistamab (Tecvayli) with subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved progression-free survival (PFS) and overall survival (OS) in patients ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...

The objective response rate was 70%, with 45% of patients achieving a complete response or better. The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic ™ (linvoseltamab ...

Lynozyfic (linvoseltamab-gcpt) is a prescription injection medicine for people with a type of blood cancer called multiple myeloma, whose cancer has come back (relapsed) or worsened (refractory) after ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...